Also known as Vasoactive Intestinal Peptide · Aviptadil · VIP
A 28-amino-acid neuropeptide and gut hormone with broad anti-inflammatory and vasodilatory activity — studied in chronic inflammatory illness and, as aviptadil, in the lung.
Research refreshed
Vasoactive intestinal peptide (VIP) is a 28-residue neuropeptide of the secretin/glucagon/VIP superfamily, released by nerves throughout the gut, lungs, and brain. It is a potent vasodilator and a broad anti-inflammatory and immunomodulatory signal, acting at the VPAC1 and VPAC2 receptors. Its synthetic form, aviptadil, has been investigated for pulmonary conditions, and VIP is used on the grey market as a nasal spray in chronic inflammatory illness protocols.
VIP is one of the body’s master anti-inflammatory signals. A 28-amino-acid member of the secretin/glucagon/VIP superfamily — a structural cousin of secretin and PACAP — it is released by nerve endings across the gastrointestinal tract, lungs, and central nervous system, where it relaxes smooth muscle, widens blood vessels, and damps down inflammatory immune activity by shifting cells away from a pro-inflammatory state.
That anti-inflammatory breadth is the basis of its research interest. Its synthetic equivalent, aviptadil, has been studied in pulmonary arterial hypertension, sarcoidosis, and acute respiratory failure. Separately, VIP has developed a following in the chronic inflammatory response syndrome (CIRS) community, where an intranasal form is used in the later stages of the mold-illness protocol popularized by Ritchie Shoemaker — a use that is neither FDA-approved nor validated by large trials. VIP is not FDA-approved; its C-terminus is amidated, a modification essential to its receptor activity.
Agonist at the VPAC1 and VPAC2 receptors (class B GPCRs), raising cAMP; produces vasodilation, bronchodilation, and a broad anti-inflammatory / immunomodulatory shift.
Behind every vial of VIP (Vasoactive Intestinal Peptide) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how VIP (Vasoactive Intestinal Peptide), specifically, is brought into being.
On paper, VIP (Vasoactive Intestinal Peptide) is C147H237N43O43S — about 3,326.8 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling VIP (Vasoactive Intestinal Peptide) means roughly 28 coupling cycles on the synthesizer — one protected residue added at a time, which is also 28 chances for an incomplete coupling to seed a deletion impurity. Its C-terminus is amidated rather than left as a free acid — a defined modification the synthesis has to deliver, not an afterthought.
The crude mixture — VIP (Vasoactive Intestinal Peptide) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of VIP (Vasoactive Intestinal Peptide) proves itself: identity confirmed by mass spectrometry against its ~3,326.8 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of VIP (Vasoactive Intestinal Peptide) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
VIP is a 28-residue C-terminally amidated neuropeptide of the secretin/glucagon family, made by solid-phase synthesis. The length drives deletion-sequence accumulation and the sequence is aggregation-prone, so coupling efficiency, the C-terminal amidation, and preparative-HPLC purification together define the quality picture.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Vasoactive Intestinal Peptide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide and gut hormone that dilates blood vessels and broadly damps inflammation, acting at the VPAC1 and VPAC2 receptors.
Anti-inflammatory and immune modulation, pulmonary conditions (as aviptadil), and — on the grey market — chronic inflammatory response syndrome (CIRS) via an intranasal form.
Intranasal VIP is used in the later stages of the Shoemaker CIRS ("mold illness") protocol. This is not an FDA-approved use and is not validated by large controlled trials.
No — VIP (and its synthetic form aviptadil) is investigational, not FDA-approved. This page is a research and educational reference.
The archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.
ViewInsulin’s counter-hormone — a 29-amino-acid peptide that raises blood glucose, the emergency rescue for severe lows, and the "G" in the new triple agonists.
ViewThe active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.